.jpeg)
2026-07-14 05:31:14
Idelalisib is an oral PI3Kδ inhibitor indicated for relapsed/refractory chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), and small lymphocytic lymphoma (SLL). The recommended dose is 150 mg twice daily. Close monitoring for severe hepatic, pulmonary, and intestinal toxicities, as well as life-threatening diarrhea, is required. This article covers indications, dosing, warnings, and adverse reactions.
2026-07-14 05:26:41
Lorlatinib is an oral tyrosine kinase inhibitor indicated for ALK-positive advanced non-small cell lung cancer (NSCLC). The recommended dose is 100 mg once daily. Treatment must be initiated by a physician experienced in anticancer therapy and preceded by ALK genetic testing. This article covers dosing, mechanism of action, common side effects, and key contraindications.
2026-07-13 07:43:38
On June 24, 2026, the FDA approved Pfizer’s Ibrance (palbociclib) in combination with anti-HER2 therapy and endocrine therapy for maintenance treatment of HR+/HER2+ advanced breast cancer, based on Phase III PATINA trial results.
2026-07-13 07:34:24
The U.S. FDA approved Gilead’s Trodelvy (sacituzumab govitecan) on June 24, 2026, for first-line treatment of advanced triple-negative breast cancer (TNBC), based on Phase III ASCENT-03 and ASCENT-04 data.
2026-07-10 06:43:53
An in-depth analysis of Cabozantinib's multi-kinase inhibition mechanism and its established role in treating renal cell carcinoma, hepatocellular carcinoma, and medullary thyroid cancer globally.
2026-07-10 06:37:28
This article provides a comprehensive overview of infusion-related reactions (IRRs) associated with Amivantamab. It covers preventive premedication, step-up dosing strategies, and protocols for managing adverse events in clinical settings.
2026-06-23 06:15:37
This article reviews clinical response patterns of margetuximab combined with chemotherapy for HER2-positive metastatic breast cancer, based on the Phase 3 SOPHIA trial. It details median time to response, RECIST evaluation cycles, key efficacy data, and factors influencing therapeutic outcomes.
2026-06-16 04:31:29
This article presents the eligible population, mechanism of action and clinical positioning of the avutometinib + defactinib combination regimen, and elaborates its clinical value and prerequisite for use in precision treatment of low-grade serous ovarian cancer.
2026-06-12 02:43:12
This article provides a comprehensive overview of vemurafenib (brand name Zelboraf), a targeted therapy for BRAF V600 mutation-positive melanoma. It covers standard dosage, administration instructions, dose adjustment principles, special population considerations, treatment monitoring requirements, and important safety information for patients and healthcare professionals.
2026-06-08 03:30:02
A comprehensive guide to the safety of Durvalumab (Imfinzi), detailing the identification, grading, and management of immune-related adverse events across multiple organ systems.
2026-06-08 03:18:47
Based on pivotal SPOTLIGHT and GLOW Phase III trials, this article analyzes the efficacy, durability of response, and real-world feedback of Zolbetuximab for advanced gastric cancer.
2026-06-08 03:13:03
A comprehensive guide to Mitotane resistance in ACC, covering its definition, mechanisms, and subsequent strategies including chemotherapy, targeted therapy, and clinical trial participation for patients and caregivers.
